Immune checkpoint blockade: The hope for immunotherapy as a treatment of lung cancer?

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 126-132

  Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84894499071     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.014     Document Type: Article

References (38)

1. C.A. Butts, M.A. Socinski, and P. Mitchell et al. START: a phase 3 study of L-BLP25 cancer immunotherapy for unresectable stage III NSCLC J Clin Oncol 27 suppl 15 2013 abstract 7500
2. K. Tanaka, K.J. Isselbacher, G. Khoury, and G. Jay Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene Science (New York, NY) 228 1985 26 30
3. A. Doyle, W.J. Martin, K. Funa, A. Gazdar, D. Carney, and S.E. Martin et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer J Exp Med 161 1985 1135 1151
4. D.P. Singal, M. Ye, and X. Qiu Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines Int J Cancer 68 1996 629 636
5. J.F. Brunet, F. Denizot, M.F. Luciani, M. Roux-Dosseto, M. Suzan, and M.G. Mattei et al. A new member of the immunoglobulin superfamily - CTLA-4 Nature 328 1987 267 270
6. T. Takahashi, T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, and N. Sakaguchi et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 J Exp Med 192 2000 303 310
7. E.M. Gabriel, and E.C. Lattime Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13 2007 785 788
8. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
9. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1 a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1995 1365 1369
10. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
11. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D.B. Flies et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Med 8 2002 793 800
12. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science (New York, NY) 271 1996 1734 1736
13. T.J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
14. M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
15. NCT01450761. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
16. P. Zatloukal, D.S. Heo, and K. Park et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive case (BSC) following first-line platinum-based therapy in patients with advanced non-small cell lung cancer J Clin Oncol 27 Suppl 15 2009: abstract 8071
17. NCT01975831. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
18. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Current Opin Immunol 24 2012 207 212
19. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, and W.H. Sharfman et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
20. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott et al. Safety, activity, and immune correlates of anti-PD-1antibody in cancer N Engl J Med 366 2012 2443 2454
21. J. Brahmer, HL, and S. Antonio et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase I trial. J Thorac Oncol 8 suppl 2 2013: abstract MO18.03
22. NCT01721759. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
23. NCT01642004. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
24. NCT01673867. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
25. NCT01454102. US National Library of Medicine. 2013. Clinicaltrials.gov (on-line).
26. E. Garon, BA, and O. Hamid et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung J Thorac Oncol 8 suppl 2 2013 abstract
27. NCT01905657. US National Library of Medicine. 2013.Clinicaltrials.gov (online)
28. NCT01840579. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
29. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
30. R. Herbst, M.S. Gordon, and G. Fine et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors J Clin Oncol 30 suppl 15 2013: abstract
31. J.C. Soria, CC, and R. Bahleda et al. Clinical activity, safety, and biomarkers of PD-L1 blockade in non-small cell lung cancer; additional analyses from a clinical study of the engineered antibody MPDL2380A (anti-PD-L1) In European Cancer Congress, Amsterdam 2013 (abstract. J Thorac Oncol. 2013;8 (suppl 2): abstract.)
32. NCT01903993. US National Library of Medicine. 2013. Clinicaltrials.gov (on-line).
33. NCT01846416. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
34. S. Khleif, LJ, and N.H. Segal et al. MEDI4736, an anti-PD-L1 antibody with engineered Fc domain preclinical evaluation and early clinical results from a Phase I study inpaitents with advanced solid tumors In European Cancer Congress, Amsterdam 2013 (abstract 802)
35. NCT01693562. US National Library of Medicine. 2013. Clinicaltrials.gov (online).
36. M.A. Postow, M.K. Callahan, C.A. Barker, Y. Yamada, J. Yuan, and S. Kitano et al. Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
37. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
38. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer Clin Cancer Res 19 2013 1021 1034